421 related articles for article (PubMed ID: 18580865)
1. Reduction of proteinuria with angiotensin receptor blockers.
Galle J
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S36-43. PubMed ID: 18580865
[TBL] [Abstract][Full Text] [Related]
2. Telmisartan in incipient and overt diabetic renal disease.
Schmieder RE; Bakris G; Weir MR
J Nephrol; 2011; 24(3):263-73. PubMed ID: 21374585
[TBL] [Abstract][Full Text] [Related]
3. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
4. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.
Barnett AH
Acta Diabetol; 2005 Apr; 42 Suppl 1():S42-9. PubMed ID: 15868119
[TBL] [Abstract][Full Text] [Related]
5. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.
Nakamura T; Fujiwara N; Kawagoe Y; Sugaya T; Ueda Y; Koide H
Eur J Clin Invest; 2010 Sep; 40(9):790-6. PubMed ID: 20584070
[TBL] [Abstract][Full Text] [Related]
6. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial.
Barnett A
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S132-5. PubMed ID: 16565237
[TBL] [Abstract][Full Text] [Related]
7. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
8. [In the DETAIL. Kidney protection in manifestations of microalbuminuria].
MMW Fortschr Med; 2006 Jun; 148(26):51. PubMed ID: 16875382
[No Abstract] [Full Text] [Related]
9. Prevention of loss of renal function over time in patients with diabetic nephropathy.
Barnett A
Am J Med; 2006 May; 119(5 Suppl 1):S40-7. PubMed ID: 16563947
[TBL] [Abstract][Full Text] [Related]
10. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive therapy with statins reduces residual albuminuria/proteinuria and provides further renoprotection by downregulating the angiotensin II-AT1 pathway in hypertensive nephropathy.
Zhang Z; Li Z; Cao K; Fang D; Wang F; Bi G; Yang J; He Y; Wu J; Wei Y; Song X
J Hypertens; 2017 Jul; 35(7):1442-1456. PubMed ID: 28244896
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.
Mazerska M; Myśliwiec M
Adv Med Sci; 2009; 54(1):37-40. PubMed ID: 19505872
[TBL] [Abstract][Full Text] [Related]
16. Effects of angiotensin II receptor blockers on diabetic nephropathy.
Kalaitzidis R; Bakris GL
J Hypertens Suppl; 2009 Jul; 27(5):S15-21. PubMed ID: 19587550
[TBL] [Abstract][Full Text] [Related]
17. Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency.
Weinbergová O; Metelka R; Vymetal J; Konecný K; Kosatíková Z
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2004 Jul; 148(1):69-73. PubMed ID: 15523550
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.
Bichu P; Nistala R; Khan A; Sowers JR; Whaley-Connell A
Vasc Health Risk Manag; 2009; 5(1):129-40. PubMed ID: 19436679
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
[TBL] [Abstract][Full Text] [Related]
20. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL; Ekhlas A; Nguyen JM; Moranne O
Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
